Neo Ivy Capital Management’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$401K Buy
+6,822
New +$286K 0.09% 234
2025
Q4
– Sell
-1,644
Closed -$56.4K – 532
2025
Q3
$56.4K Buy
+1,644
New +$47.2K 0.01% 339
2025
Q2
– Sell
-5,838
Closed -$173K – 485
2025
Q1
$173K Buy
+5,838
New +$223K 0.06% 227
2024
Q4
– Sell
-24,116
Closed -$820K – 410
2024
Q3
$820K Buy
+24,116
New +$678K 0.27% 145
2022
Q2
– Sell
-1,652
Closed -$46K – 626
2022
Q1
$46K Buy
1,652
+946
+134% +$27.1K 0.04% 381
2021
Q4
$29K Buy
+706
New +$31.2K 0.04% 338
2021
Q3
– Sell
-3,741
Closed -$150K – 635
2021
Q2
$150K Buy
3,741
+3,121
+503% +$133K 0.15% 216
2021
Q1
$33K Sell
620
-3,363
-84% -$194K 0.04% 367
2020
Q4
$195K Buy
+3,983
New +$185K 0.22% 166

Other funds holding VCYT

Neo Ivy Capital Management's VCYT Position: Q2 2026 in Review

Neo Ivy Capital Management opened a new position in Veracyte (VCYT) in Q2 2026: 6,822 shares worth $401K. The stake represents 0.09% of the portfolio and ranks #234 among its holdings. This is a return to the name: Neo Ivy Capital Management previously reported a position in VCYT as recently as Q3 2025.

Neo Ivy Capital Management first reported a position in VCYT in Q4 2020 and has held it in 9 quarters since. The position peaked at $820K in Q3 2024. 370 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • Neo Ivy Capital Management held 6,822 shares of Veracyte worth $401K as of Q2 2026.
  • Veracyte was a new Neo Ivy Capital Management position in Q2 2026.
  • Veracyte made up 0.09% of Neo Ivy Capital Management's portfolio in Q2 2026, its #234 holding.
  • Neo Ivy Capital Management first reported a position in Veracyte in Q4 2020 and has held it in 9 quarters since.
  • Neo Ivy Capital Management's Veracyte position peaked at $820K in Q3 2024.
  • 370 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.